Melissa Busch, LabPulse.com assistant editor; Emily Hayes, editor in chiefHPVHPV, Pap cotesting best for cervical cancer detection in Quest studyCotesting involves Pap and HPV screening using the same specimen. A new study of women 30 years or older by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center found that cotesting outperformed HPV or Pap testing alone for detecting precancer or cancer. In the retrospective study, the researchers evaluated deidentified results for tests conducted between 2010 and 2018 by Quest in 13.6Â million women; 8,059 had precancers and 1,259 were subsequently diagnosed with cervical cancer.July 8, 2020Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community